Bradbury Brian D, Chen Fangfei, Furniss Anna, Pisoni Ronald L, Keen Marcia, Mapes Donna, Krishnan Mahesh
Department of Biostatistics and Epidemiology, Amgen Inc, Thousand Oaks, CA 91320, USA.
Am J Kidney Dis. 2009 May;53(5):804-14. doi: 10.1053/j.ajkd.2008.11.031. Epub 2009 Mar 5.
Limited data exist describing vascular access conversions during the first year on dialysis therapy or the effect of converting to and from a catheter on subsequent mortality risk.
Retrospective cohort study.
SETTING & PARTICIPANTS: We studied a random sample of incident US hemodialysis patients (initiated long-term dialysis < 30 days before study entry) in the Dialysis Outcomes and Practice Patterns Study (DOPPS; 1996-2004).
At dialysis therapy initiation, we assessed vascular access type in use (arteriovenous fistula [AVF], arteriovenous graft [AVG], or catheter) and other patient characteristics. We characterized changes in vascular access type (conversions) by using regularly collected functional status information.
OUTCOME & MEASUREMENTS: We assessed time to all-cause mortality. We first described conversions, then used time-dependent Cox regression to estimate mortality hazard ratios (HRs) for conversions from a catheter to a permanent vascular access (versus no conversion) and conversions from a permanent vascular access to a catheter (versus no conversion).
The study included 4,532 patients; 69.2% were dialyzing with a catheter; 17.6%, with an AVG; and 13.1%, with an AVF. In patients initiating therapy with an AVF or AVG, 22% experienced a conversion (failure), and median times to first failure were 62 and 84 days, respectively. In catheter patients, 59% converted to an AVF/AVG (predominantly AVG [57%]); median times to first conversion were 92 and 66 days, respectively. Conversion to a permanent access was associated with an adjusted mortality HR of 0.69 (95% confidence interval, 0.55 to 0.85). The effect was similar for conversion to an AVF or AVG, and these persisted across demographic groups and facilities with different conversion practices. Conversion from a permanent vascular access to a catheter was associated with an adjusted mortality HR of 1.81 (95% confidence interval, 1.22 to 2.68).
Potential for residual confounding because of unmeasured factors influencing decision to convert.
Vascular access conversions are common in incident patients. Continued efforts to increase early nephrologist referral and permanent vascular access placement may help decrease mortality risk in incident dialysis patients.
关于透析治疗第一年期间血管通路转换情况,或导管置入与拔除对后续死亡风险的影响,现有数据有限。
回顾性队列研究。
我们在透析预后与实践模式研究(DOPPS;1996 - 2004年)中,对美国初治血液透析患者(研究入组前<30天开始长期透析)的随机样本进行了研究。
在开始透析治疗时,我们评估了所使用的血管通路类型(动静脉内瘘[AVF]、动静脉移植物[AVG]或导管)以及其他患者特征。我们通过定期收集的功能状态信息来描述血管通路类型的变化(转换情况)。
我们评估了全因死亡时间。我们首先描述了转换情况,然后使用时间依赖性Cox回归来估计从导管转换为永久性血管通路(与未转换相比)以及从永久性血管通路转换为导管(与未转换相比)的死亡风险比(HRs)。
该研究纳入了4532例患者;69.2%使用导管进行透析;17.6%使用AVG;13.1%使用AVF。在以AVF或AVG开始治疗的患者中,22%经历了转换(失败),首次失败的中位时间分别为62天和84天。在使用导管的患者中,59%转换为AVF/AVG(主要是AVG[57%]);首次转换的中位时间分别为92天和66天。转换为永久性通路与调整后的死亡HR为0.69相关(95%置信区间,0.55至0.85)。转换为AVF或AVG的效果相似,并且在不同人口统计学组和具有不同转换实践的医疗机构中均持续存在。从永久性血管通路转换为导管与调整后的死亡HR为1.81相关(95%置信区间,1.22至2.68)。
由于影响转换决策的未测量因素,存在残余混杂的可能性。
初治患者中血管通路转换很常见。持续努力增加早期肾病专家转诊和永久性血管通路置入,可能有助于降低初治透析患者的死亡风险。